Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Guardant Health, Inc.

Guardant360 CDx

Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics.

Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.

Guardant Health

‘Revolutionizing Colorectal Cancer Screenings’: Our Chief Medical Officer Dr. Craig Eagle highlights why developing accessible testing to screen for #ColorectalCancer is crucial, and how blood-based screening can overcome current barriers. 

"When it's caught early, you can have up to 91% survival at five years. And we're talking about cancer, which can be scary. If it's left to spread, that's a lot wider, the chance of surviving that five years drops down."

Patients and doctors agree that blood tests could help close the #ColorectalCancer screening gap in new The Harris Poll survey results announced during Colorectal Cancer Awareness Month.

We commissioned the survey to better understand the reasons why people decide to get screened or not.

We are looking forward to the 3rd annual NeauxCancer Conference by Cancer Advocacy Group of Louisiana (CAGLA) where our Co-CEO AmirAli Talasaz will participate as a keynote speaker.

We're proud to sponsor the 8th Annual Liquid Biopsy for Precision Oncology Summit later this month in San Diego. Our Clinical Evidence Director Thereasa Rich will help kick off the summit by delivering a talk on the potential for MRD and longitudinal monitoring tests to accelerate clinical trials.

Later in the day, our team will participate on a panel about advancing precision oncology globally through improved access to liquid biopsy.

More details: https://lbx-summit.com/

As part of #BlackHistoryMonth, we asked Guardant Health employees to share what the month means to them. For our Clinical Oncology Specialist Candice, it's a time to look back and celebrate past achievements while being cognizant of the work that still needs to be done.

What does Black History Month mean to you?

COM:GUARDANTHEALTH

Guardant Health, Inc.

Last Close

28.59

08/11 21:00

Market Cap

3.38B

Beta: -

Volume Today

2.74M

Avg: -

Financials Not Available